If you’ve seen a diagnosis or test result mentioning “17q12 deletion syndrome,” an unfamiliar term like this can be unsettling.
Here is the conclusion first: this condition is a rare genetic disorder caused by the loss of a region on the long arm of chromosome 17 that includes the HNF1B gene. It mainly affects kidney structure or function, causes a form of diabetes that appears at a young age, and can involve developmental traits — and how these show up varies widely from person to person.
This article walks through the underlying chromosomal change, the main symptoms, how it is inherited, its relationship to prenatal testing and NIPT, the path to a definitive diagnosis, and treatment and family support. We draw on public and academic sources such as GARD (part of the U.S. National Institutes of Health) and the medical literature. Because information on this rare condition can be scattered, let’s go through it step by step rather than let isolated facts fuel anxiety.
💡 What this article covers
- What kind of chromosomal change 17q12 deletion syndrome is (the HNF1B gene and the roughly 1.4–1.5 Mb recurrent deletion)
- The main symptoms — kidney abnormalities, MODY5 diabetes, neurodevelopmental conditions — and how often each is reported
- How it is inherited (de novo vs. familial transmission) and what that means for a future pregnancy
- When this condition is, and is not, covered by prenatal testing and NIPT
- The testing pathway to a definitive diagnosis, including chromosomal microarray analysis
- The treatment approach and the support options families can rely on
1. What Is 17q12 Deletion Syndrome? (The Underlying Chromosomal Change)
17q12 deletion syndrome is a contiguous gene syndrome caused by the loss, from birth, of a region on the long arm of chromosome 17 (17q12) that includes the HNF1B gene. It is also called “17q12 recurrent deletion syndrome.”
Across most reported cases, the deleted region is remarkably consistent, at roughly 1.4–1.5 megabases (Mb). This region is reported to contain 15 or more genes, including HNF1B. Because the chromosome carries matching repeat sequences on either side of this region, homologous recombination between them tends to produce the same deletion repeatedly — which is why the pattern recurs so consistently across unrelated individuals.
What Does the HNF1B Gene Do?
HNF1B encodes a protein (a transcription factor) involved in the development of the kidneys, pancreas, liver, brain, and reproductive organs. During fetal development, it helps regulate the activity of many other genes as these organs are formed.
Because the entire region containing this gene is lost, effects tend to extend beyond the kidneys to multiple organs. GARD, the Genetic and Rare Diseases Information Center run by the U.S. National Institutes of Health, describes this condition around three main pillars: kidney abnormalities, diabetes, and neurodevelopmental conditions.
Large population-based studies put the frequency at roughly 1 in 6,250. Among microdeletion syndromes, that makes it relatively common.
2. How It Differs from an HNF1B “Point Mutation”
The same gene name, HNF1B, is involved in two different situations — loss of the entire gene versus a change within just part of the gene — and the range of resulting symptoms differs between them.
| Comparison | HNF1B point mutation (Renal Cysts and Diabetes Syndrome) | 17q12 deletion syndrome (this article) |
|---|---|---|
| Genetic change | A change within just part of the HNF1B gene | Deletion of an entire region of roughly 15 genes around and including HNF1B |
| Main symptoms | Mainly kidney abnormalities and diabetes | Kidney abnormalities and diabetes, plus a higher reported rate of neurodevelopmental conditions |
| Other name | RCAD (Renal Cysts and Diabetes syndrome) | 17q12 recurrent deletion syndrome |
| Neurodevelopmental involvement | Not considered a core feature | Developmental delay or autism spectrum-related traits reported in roughly half of cases |
When only a point mutation is present, kidney and diabetes issues tend to dominate the clinical picture. With a full deletion, the neighboring genes are lost as well, which is thought to add a neurodevelopmental dimension more often. If a test report simply says “HNF1B,” it’s worth confirming with your physician whether it reflects a point mutation or a deletion, since the expected course can differ.
3. Main Symptoms
Kidney abnormalities, early-onset diabetes, and neurodevelopmental conditions are the three hallmark features, and how — and how severely — they appear varies considerably from person to person. GARD summarizes the approximate reported frequencies as follows.
| Symptom category | Approximate reported frequency |
|---|---|
| Kidney abnormalities (structural or functional issues such as multiple renal cysts, renal dysplasia, or horseshoe kidney) | About 85–90% |
| MODY5 (Maturity-Onset Diabetes of the Young, type 5) | About 40% (most diagnosed before age 25) |
| Neurodevelopmental and psychiatric conditions (developmental delay, autism spectrum disorder, ADHD, schizophrenia, and others) | About 50% |
Kidney abnormalities are the most frequently reported feature, and in many cases they are first noticed on prenatal ultrasound as renal cysts or enlarged kidneys. Regardless of whether symptoms are visible at birth, ongoing, long-term monitoring is essential — kidney function can decline gradually and only become apparent over time.
The diabetes involved works through a different mechanism than autoimmune type 1 diabetes. It stems from reduced function of the insulin-producing cells in the pancreas themselves, and it tends to appear from adolescence into early adulthood.
On the neurodevelopmental side, some children show slower language or motor development, and some have traits associated with autism spectrum disorder. Anxiety or mood fluctuations have been reported to emerge in adulthood in some cases, but a good number of individuals show no developmental concerns at all.
Other findings can include mildly abnormal liver function tests, pancreatic hypoplasia, and, in females, uterine structural anomalies. None of these occur in every individual, and GARD, run by the U.S. National Institutes of Health, likewise emphasizes just how much variation exists between individuals.
If you’d like to read more about developmental traits, see our article on NIPT and Autism/Developmental Disorders (Japanese), and for individual variation in intellectual development, see What NIPT Reveals About Intellectual Disability (Japanese).
4. Cause and Inheritance Pattern (De Novo vs. Familial Transmission)
About 75% of cases arise from a spontaneous (de novo) mutation, and the remaining 25% or so are inherited from a parent. Even within the same family, the deletion can produce very different symptoms from one person to the next.
De Novo (Spontaneous) Cases
A chance, copy-error-like change can occur during the formation of an egg or sperm, or during the earliest cell divisions right after fertilization. It is not caused by anything in a pregnant woman’s diet, lifestyle, or work. In clinic visits, I always make a point of telling parents that there is no reason to blame themselves.
Familial Transmission and Dominant Inheritance
17q12 deletion syndrome follows an autosomal dominant pattern of inheritance (a single copy inherited from one parent is enough to cause the condition). If one parent carries the same deletion, there is roughly a 50% chance of passing it on to each future child.
What’s notable is that, even within families sharing the identical deletion, kidney findings and developmental features can differ substantially from one relative to the next. This reflects variable “penetrance” and “expressivity” — there are documented cases where a parent turned out to have only a mild kidney cyst and had never been diagnosed.
Once a child is diagnosed, chromosomal microarray testing of both parents can determine whether the deletion is de novo or inherited — an important step for understanding the implications for future pregnancies. If you have questions about a future child, genetic counseling with a certified clinical geneticist or genetic counselor is the recommended next step.
5. Relationship to Prenatal Testing and NIPT
A deletion in the 17q12 region is not included in standard NIPT panels; it only becomes a candidate finding on expanded panels that also screen for microdeletions.
Standard NIPT mainly screens for changes in the “number” of chromosomes — trisomy 21, 18, and 13. Some plans also include a subset of relatively common microdeletions, such as 22q11.2 deletion syndrome (DiGeorge syndrome). At Hiro Clinic, our expanded NIPT panel covers 143 conditions, including microdeletions and duplications, and the 17q12 region is among the conditions it can flag.
In practice, involvement of the 17q12 region sometimes comes up during genetic counseling after a prenatal ultrasound shows enlarged kidneys on both sides, or renal cysts. Kidney findings appearing first, ahead of any genetic test, is one of the distinctive features of this condition.
It’s important to keep in mind that NIPT is a non-diagnostic screening test. The NIPT guidelines from the Japan Society of Obstetrics and Gynecology (Japanese) likewise state that NIPT results fall within the scope of screening and do not constitute a definitive diagnosis. A report from Japan’s Ministry of Health, Labour and Welfare expert committee on NIPT and prenatal testing (Japanese) similarly notes that expanded panels covering microdeletions have limits to their analytical and clinical validity.
If NIPT returns a positive finding for a microdeletion involving the 17q12 region, the first step is genetic counseling to understand what the result actually means. From there, you and your partner can decide together, with guidance, whether to pursue chromosomal microarray analysis via amniocentesis. Because this is a very rare condition, it is best to avoid drawing firm conclusions from a positive screen alone and to work through the details with specialists, one step at a time.
6. The Path to a Definitive Diagnosis
Chromosomal microarray analysis (CMA) — a high-resolution genetic test — plays the central role in confirming the diagnosis.
Chromosomal Microarray Analysis (CMA)
CMA can detect microdeletions and duplications on the scale of hundreds of kilobases to several megabases — changes too small for conventional microscope-based karyotyping (G-banding) to pick up. It is performed on amniotic fluid before birth or on a blood sample after birth, and it can map the exact extent of the deletion in detail.
FISH Testing and Parental Testing
FISH testing, which lights up a specific region of a chromosome for direct visual confirmation, is sometimes used to support the diagnosis. Testing both parents’ blood can also determine whether the deletion arose de novo or was inherited.
Postnatal Evaluation
After diagnosis, the child’s overall condition is assessed through a combination of renal ultrasound, kidney function testing, blood glucose checks, and developmental assessments. Because kidney status can change over time as a child grows, ongoing, regular follow-up is essential.
7. Treatment and Support
There is no way to restore the missing chromosomal segment, so no cure exists yet — but specialized management of the kidneys, diabetes, and development, combined with the right support, can help a child grow and thrive.
- Kidney management: Working with a pediatric nephrologist for regular kidney function tests and blood pressure monitoring. If kidney function declines significantly, dialysis or transplantation may eventually be considered.
- Diabetes management: Blood sugar is controlled through diet, oral medication, or insulin therapy as needed. The age of onset and rate of progression vary from person to person.
- Developmental support: Physical therapy (PT), occupational therapy (OT), and speech and language therapy (ST) help support progress in movement, communication, and daily living skills.
- Choosing an educational setting: Working with local education support services to find the right fit — whether a special-needs school, a special-needs classroom, or a resource room — based on the child’s individual needs.
Because the combination and severity of symptoms differ from person to person, there is no single fixed course this condition always follows. Nephrology, endocrinology, and pediatric neurology — among other specialties — typically work together, building a support plan tailored to each child step by step.
8. Prognosis and Outlook
Kidney function and developmental outcomes vary widely, and early, ongoing kidney monitoring together with developmental support are what most shape quality of life.
Some individuals reach adulthood with only mild kidney involvement and no notable diabetes or developmental delay, while others experience progressive kidney decline that eventually requires dialysis or transplantation. This difference is thought to reflect both the extent of the deletion and individual variation in penetrance.
Given how few cases have been studied, it remains difficult to state a definitive long-term trajectory. What matters most is regular kidney function testing for early detection, paired with consistent day-to-day care — that combination is, in our view, the most realistic path to preserving quality of life.
9. Support for Families, and Thinking About a Future Pregnancy
The isolation that comes with a rare condition can feel significant, but genetic counseling, patient support groups, and public consultation services are all resources you can lean on.
Finding another family nearby dealing with the same condition may be difficult. Even so, connections with other families affected by chromosome-related rare conditions, and the specialized support genetic counselors provide, are both real resources you can draw on. Medical management is best left to physicians and developmental-support staff — a family’s role, as we see it, is to share in celebrating each small step of a child’s growth.
If you’d like to learn about other microdeletion syndromes, or other conditions involving chromosome 17, the articles below may help.
If you’re concerned about microdeletions in general, our article on The Hidden Risks of Chromosomal Microabnormalities may also be useful.
If you’re considering NIPT for a future pregnancy, how far the panel extends into microdeletions will shape which plan is right for you. If you’re not sure which plan fits your situation, try our Plan Finder (Japanese). Phone consultations are also welcome — feel free to reach us at 0120-169-629.
Frequently Asked Questions
Are 17q12 deletion syndrome and an HNF1B point mutation (RCAD) the same condition?
Strictly speaking, they are considered distinct. A point mutation confined to the HNF1B gene mainly causes kidney abnormalities and diabetes, while 17q12 deletion syndrome involves loss of the surrounding genes as well, which is reported to raise the frequency of neurodevelopmental conditions.
Does this condition always cause diabetes?
Not always. About 40% of individuals develop MODY5, a form of early-onset diabetes, while a substantial share never develop diabetes at all. Age of onset and progression also vary from person to person.
Can a deletion in the 17q12 region be detected by NIPT?
It is not typically included in standard NIPT panels; it can come up as a candidate finding on expanded panels that also screen for microdeletions. Because NIPT is a non-diagnostic test, a positive finding needs to be confirmed with a diagnostic test such as amniocentesis.
Is this hereditary? Could it affect a future child?
About 75% of cases occur as a spontaneous (de novo) mutation, and the recurrence risk for a future child is generally considered low in those cases. However, if either parent carries the same deletion, there is roughly a 50% chance of passing it on — genetic counseling can help clarify your specific situation.
What test confirms the diagnosis?
Chromosomal microarray analysis (CMA) is the primary diagnostic test. It can detect microscopic deletions that conventional microscope-based testing would miss, with FISH testing or parental testing used for confirmation as needed.
How often do kidney abnormalities occur?
Reports put this at around 85–90%, the highest frequency among the reported symptoms. Findings vary — multiple renal cysts and renal dysplasia are both common — and they are frequently first noticed on prenatal ultrasound.
Medically reviewed by: Hiroshi Oka / Director-General and Laboratory Director, Hiro Clinic, operated by the Fukumi-kai Medical Corporation. Graduate of Keio University School of Medicine. Licensed to practice medicine in both Japan and the United States, and holds a medical doctorate (PhD). One of a small number of physicians in Japan to hold Laboratory Director credentials. This article is prepared in line with Japan’s medical advertising guidelines and draws on public and academic sources including GRJ (Japanese), GARD, the Japan Society of Obstetrics and Gynecology, Japan’s Ministry of Health, Labour and Welfare, and the Japan Intractable Diseases Information Center. Because this is a rare condition with a limited number of reported cases, reported frequencies and figures vary across the literature. Please consult your physician for decisions on diagnosis and treatment.
日本皮膚科学会 皮膚科専門医／日本医師会 産業医／東京衛生検査所 指導監督医
この記事は、 ヒロクリニックNIPTの編集・監修体制 にもとづき、資格を持つ医師が内容を確認しています。
